Liek s účinnou látkou palivizumab
Slovakia · Banská Bystrica · how to bid here →
Your path to submission
- Deadline: 28 September at 00:00 — 9 days left.
- The submission point is stated in the notice (link on the right).
- Collect your evidence — the eligibility requirements are listed above; for many of them the analysis explains how to obtain them.
Clement What the numbers say about this buyer
- 10% of this buyer's awards went to companies that had already won here before (61 awards since 2018, spread over 5 companies). That is well below the sector norm (64%) — this buyer switches suppliers more often than others.n = 61 awards since 2018
- In this sector the buyer awards roughly every 3 months (10 awards, most recently September 2026) — the next award is due around December 2026 by that rhythm. The last award went to PHOENIX Zdravotnícke zásobovanie, a.s..n = 10
- 22% of the bids received came from small and medium-sized enterprises (11 procedures with a bid mix). Sector: 72%.n = 11
- 26% of awards went to companies from abroad (61 awards with a known winner country). Sector average: 11%.n = 61
- The award came in at a median 102% of the estimated value (8 awards with both estimate and value) — pricing at the estimate is usually about right here. Sector: 91%.n = 8
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 13/09/2026.
Foreign bidders
In Slovakia · Medical equipment & pharma, 17 contracts went to foreign companies over the last 3 years (of 1,829 recorded awards).
Typical field: median 1 (from 10 awards).
What the buyer is looking for
The summary in English is being prepared. The official description below is in the original language (DE).
Show original description (DE)
Predmetom zákazky je: Liek s účinnou látkou palivizumab Palivizumab je rekombinantná humanizovaná monoklonálna protilátka vyrobená technológiou DNA v hostiteľských bunkách myelómu myší. Jedna 0,5 ml injekčná liekovka obsahuje 50 mg palivizumabu Liek je indikovaný na prevenciu závažného ochorenia dolných dýchacích ciest vyžadujúceho hospitalizáciu, ktoré je vyvolané respiračným syncyciálnym vírusom (RSV) u detí s vysokým rizikom ochorenia RSV: • deti, ktoré sa narodili v 35. týždni gravidity alebo skôr a na začiatku sezóny RSV sú mladšie ako 6 mesiacov; • deti do 2 rokov, u ktorých bola v posledných 6 mesiacoch potrebná liečba bronchopulmonálnej dysplázie; • deti do 2 rokov s hemodynamicky signifikantným vrodeným srdcovým ochorením
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| MED - ART, spol. s r.o. | 6 | 2025 |
| PHOENIX Zdravotnícke zásobovanie, a.s. | 2 | 2024–2026 |
| BLUEMED s.r.o. | 1 | 2024 |
| Pragolab s.r.o. | 1 | 2024 |
| ELMED, s.r.o. | 1 | 2025 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.